GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion. Wide-moat GSK’s third-quarter earnings aligned with our ...

the drugmaker’s senior vice president of oncology global product strategy. Enter: “Your Cancer Is Our Challenge,” a new ...

and robust product delivery practices, including building supply capacity. The drugmaker's chief executive, Emma Walmsley noted this is the eighth time that GSK had headed the list, and comes ...

While GSK insists it is still firmly focused on R&D, the company has latterly started to increase its portfolio of high-volume, lower-priced products, such as vaccines and consumer healthcare ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...